Topic of Study: Breast Cancer This is a Phase 3 open-label, randomised study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab versus investigator’s choice of therapy in patients with Stage I-III Triple-negative breast cancer who have residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following Neoadjuvant Systemic Therapy. (Clinicaltrials.gov ID#: NCT05629585)

Topic of Study: Inflammatory Bowel Disease This is a pragmatic, open-label, multicenter randomized controlled trial conducted in asymptomatic patients with IBD who have persistent moderate to severe endoscopic inflammation despite optimization of index targeted immunomodulatory (TIM). This clinical trial aims to collect and analyze data in patients with IBD who are currently receiving IBD medication(s) that targets their immune system (TIM) in routine clinical care, and to determine if switching to an alternative IBD medications will improve their disease outcome without increasing the burden of their treatment. (Clinicaltrials.gov ID# NCT05230173)

Topic of Study: Inflammatory Bowel Disease This is a phase III, multicenter, double-blind, placebo-controlled, treat-through study. The goals of this clinical trial are to evaluate the efficacy and safety of RO7790121 compared with placebo in inducing and maintaining remission in patients with moderately to severely active Crohn's Disease and Ulcerative colitis.

Topic of Study: Gastrointestinal Disease This study is a phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of cenicriviroc for the treatment of liver fibrosis in adult subjects with nonalcoholic steatohepatitis. (AURORA)

Topic of Study: Appendiceal Cancer

This study is a phase II, open label, historical controlled study to determine the impact of antibiotic therapy on the disease progression and overall survival of the patients with Pseudomyxoma Peritonei (PMP). The study will examine the use of the antibiotic PREVPAC, in patients undergoing CRS/HIPEC for appendiceal neoplasms with peritoneal dissemination and its effect on patient outcomes and survival. (ClinicalTrials.gov ID#: NCT02387203)

Topic of Study: Breast Cancer This is a study of RO7247669 + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in participants with previously untreated, PD-L1-Positive, locally-advanced unresectable or metastatic Triple-Negative breast cancer. (Clinicaltrials.gov ID#: NCT05852691)

Topic of Study: Breast Cancer This is a randomized Phase III trial comparing active symptom monitoring plus patient education versus patient education alone to improve persistence with endocrine therapy in young women with Stage I-III breast cancer (Aspen). (Clinicaltrials.gov ID#: NCT05568472)

Topic of Study: Appendiceal Cancer The primary aim of the study is to determine whether the gastrointestinal microbiome of appendiceal cancer patients with peritoneal spread differs from a healthy, age-matched cohort of the American population. This is a collaborative study with the University of California, San Diego and Rob Knight, PhD who will perform the genetic analysis of bio-specimens from patients who undergo cytoreductive surgery with HIPEC. (Clinical Trials ID #: NCT02599116)

Topic of Study: Breast Cancer

This study is designed for patients desiring nipple reconstruction following surgery for breast cancer and breast reconstruction. Eligible patients will receive a surgical procedure to reconstruct one or both nipples utilizing the COOK® Biodesign® Plastic Surgery Matrix. The study is designed to evaluate the benefit of this device in achieving effective and aesthetic nipple reconstruction. Patients will be evaluated at the time of the procedure and at 1 week, 4 weeks, 3 months, 6 months, and 12 months after surgery to examine the projection of their reconstructed nipple(s) and patient satisfaction (Cook Medical Study 09-009; Clinicaltrials.gov ID#: NCT01216319).

Topic of Study: Breast Cancer This is a randomized, open-label, Phase 3 study of Sacituzumab Govitecan versus treatment of physician's choice in patients with previously untreated, locally advanced, inoperable or metastatic Triple-Negative breast cancer whose tumors do not express PD-L1 or in patients previously treated with Anti-PD-(L)1 Agents in the early setting whose tumors do express PD-L1. (Clinicaltrials.gov ID#: NCT05382299)